33.41

1.09% 0.36

After Hours: 33.41

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $33.41, with a volume of 611.14K. It is up +1.09% in the last 24 hours and down -3.44% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Previous Close:

$33.05

Open:

$32.45

24h Volume:

611.14K

Relative Volume:

0.94

Market Cap:

$1.88B

Revenue:

$656.11M

Net Income/Loss:

$114.99M

P/E Ratio:

13.58

EPS:

2.46

Net Cash Flow:

$212.78M

1W Performance:

-19.47%

1M Performance:

-3.44%

6M Performance:

+5.83%

1Y Performance:

+28.90%

1-Day Range:

$32.37

$33.58

1-Week Range:

$31.02

$38.00

52-Week Range:

$22.89

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

246

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

08:08 AM

AlphaCentric Advisors LLC Reduces Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat

08:08 AM

05:53 AM

There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings - Yahoo Finance

05:53 AM

Nov 02, 2024

HRMY vs. REGN: Which Stock Is the Better Value Option? - MSN

Nov 02, 2024

(HRMY) Trading Signals - Stock Traders Daily

Nov 02, 2024

Nov 01, 2024

Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 01, 2024

Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

Harmony Bio, The No. 1 Biotech Stock, Surges On Its 'High Quality' Beat - MSN

Oct 31, 2024

Harmony Biosciences Holdings Prices of Public Offering of Common Stock - citybiz

Oct 31, 2024

Harmony Biosciences chief commercial officer sells $870,018 in stock - Investing.com

Oct 31, 2024

Harmony Biosciences chief commercial officer sells $870,018 in stock By Investing.com - Investing.com Canada

Oct 31, 2024

Latham Advises Harmony Biosciences Holdings, Inc. in Public Offering of Common Stock by Selling Shareholders - ILW.com

Oct 31, 2024

HRMY Makes Notable Cross Below Critical Moving Average - Nasdaq

Oct 31, 2024

Harmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat

Oct 31, 2024

Cantor Fitzgerald Issues Positive Estimate for HRMY Earnings - MarketBeat

Oct 31, 2024

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024

Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next - Simply Wall St

Oct 31, 2024

Goldman Sachs maintains sell rating on HRMY stock with $28 target - Investing.com Canada

Oct 31, 2024

Top 5 US Stocks To Buy In October 2024 - Investing.com

Oct 31, 2024

Oct 30, 2024